Trial · NCT02242695
Registered outcomes26
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 26
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Clinical cure rate | Control 1 at day 4 after therapy end | Clinical cure rate is defined as Total Severity Score (TSC) ≤ 2 |
| Secondary | Microbiological cure rate | Control 1 at 4 days after therapy end | Negative microscopy for showing yeast forms (hyphae/pseudohyphae) or budding yeasts and Negative Candida culture |
| Secondary | Therapeutic cure rate | Control 1 at 4 days after therapy end | Clinically and microbiologically cured |
| Secondary | Individual clinical signs and symptoms | Control 1 at 4 days after therapy end | 4-point rating scale for vaginal itching, vaginal burning or soreness, vulvo/vaginal erythema or edema, and vulvar excoriation ofr fissure formation |
| Secondary | Presence of dyspareunia | Control 1 at 4 days after therapy end | yes/no |
| Secondary | Direct microscopy (wet smear) | Control 1 at 4 days after therapy end | Presence or absence of Candida hyphea or spores |
| Secondary | vaginal pH | Control 1 at 4 days after therapy end | |
| Secondary | Candida culture | Control 1 at 4 days after therapy end | positive / negative for Candida spp |
| Secondary | Global assessment of efficacy | Control 1 at 4 days after therapy end | 4-point rating scale assessed by investigator and patient |
| Secondary | Patient Satisfaction | Control 1 at 4 days after therapy end | presence of vaginal discomfort, increased discharge, burning sensation |
| Secondary | Adverse event | Control 1 at 4 days after therapy end | Number of participants experiencing an adverse event |
| Secondary | Global assessment of tolerability | Control 1 at 4 days after therapy end | 4-point rating scale by investigator and patient |
| Secondary | Clinical cure rate | Control 2 at 6 weeks after therapy end | Clinical cure rate defined as Total Symptom Score TSC ≤ 2 |
| Secondary | Presence of external dysuria | Control 1 at 4 days after therapy end | yes/no |
| Secondary | Microbiological cure rate | Control 2 at 6 weeks after therapy end | Negative microscopy for showing yeast forms (hyphae/pseudohyphae) or budding yeasts and Negative Candida culture |
| Secondary | Therapeutic cure rate | Control 2 at 6 weeks after therapy end | Clinically and microbiologically cured |
| Secondary | Individual clinical signs and symptoms | Control 2 at 6 weeks after therapy end | 4-point rating scale for vaginal itching, vaginal burning or soreness, vulvo/vaginal erythema or edema, and vulvar excoriation ofr fissure formation |
| Secondary | Presence of dyspareunia | Control 2 at 6 weeks after therapy end | yes/no |
| Secondary | Direct microscopy (wet smear) | Control 2 at 6 weeks after therapy end | Presence or absence of Candida hyphea or spores |
| Secondary | vaginal pH | Control 2 at 6 weeks after therapy end |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02242695/registered